Home
overview

SMi are proud to present the 3rd Annual Orphan Drugs and Rare Diseases Conference.

The Orphan Drugs market is set to rise as a result of pharmaceutical companies now looking to orphan drugs as an essential revenue stream with 2014 set to be the year to see Orphan adoption!

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further commercialisation and developments.

With collaboration being a key topic of discussion, the conference will enable all those involved to discuss Market Access, Pricing and Reimbursement, Patient Engagement and Recruitment, with an insight into Regulatory Requirements.
 

SMi are providing a platform for all stakeholders, inclusive of small biotechs, pharmaceutical companies, patient advocacy organisations, researchers and regulators to share perspectives and expertise to drive the field of Orphan Drugs and Rare Diseases forward.

Hear important insights from Ian Hudson, CEO, MHRA on the Early Access to Medicines Initiative and adaptive licensing
• Focus on enhancing development pathways, with the growth of the commercial pipeline for orphan drugs and rare diseases
• Assess tools for consideration to gain early market access and enhance patient recruitment
• Interactive round table discussion led by Dominic Nutt, Director of Communications, The Saatchi Cancer Initiative, M&C Saatchi on creating a culture of innovation in the field of orphan drugs and rare diseases

 • CEO
• CSO
• COO
• CCO
• Head of Regulatory Affairs
• Head of Market Access
• Head of Medical Affairs
• Head of Patient Advocacy
• Head of Clinical Research
• Head of Manufacturing
• Head of Brand Management
 
 

AKU Society; Alexion Pharmaceuticals Inc; Astellas; Baxter A G; BioMed Central; Boehringer Ingelheim; Cambridge Cognition ; Clinigen GAP; Covington & Burling; Findacure Foundation; Freelance journalist; Genethon; Genzyme Corporation; GlaxoSmithKline; Glythera; GW Pharmaceuticals Ltd; IGES Institut.; Informa Professional; Justpharmareports; KOWA; Linde AG; LSE Health and Social Care; Novabiotics Ltd; Novartis International AG; Novo Nordisk A/s; Pfizer; PHMR Associates; Quintiles; Roche; Roche Pharmaceuticals; Roche Products; Royal Holloway University of London; Scrip Intelligence; Shire Pharmaceuticals; Shire Pharmaceuticals Group Plc; Shire plc; sigma-tau Pharma Ltd; Tarix Pharmaceuticals; Thomson Reuters; Tikomed; Transgene SA; Tudor Reilly Health; University Of British Columbia; University Of Newcastle; University of Newcastle upon Tyne; Zambon Spa; Ziarco Pharma;

Conference programme

8:30 Registration & Coffee

9:00 Chairs Opening Remarks

Sylvain Forget

Sylvain Forget, COO, GMP Orphan SAS

9:10 Why are Orphan Drugs different? - Achieving sustainable access for Orphan Drugs in Europe

Gunter  Harms

Gunter Harms , Market Access & Public Affairs Director, Shire Pharmaceuticals

  • EU OMP regulation and importance of national rare disease plans
  • Specific Market Access challenges for OMPs
  • The challenge of demonstrating value for OMPS
  • Shire engagement to address these challenges; Examples
  • 9:50 Keynote Address: Review - Earlier patient access to medicines

    Daniel  O'Connor

    Daniel O'Connor, Medical Assessor, MHRA

  • The UK Early Access to Medicines Scheme (EAMS)
  • What to expect and what’s required for the promising innovative medicine designation and the scientific opinion
  • EU adaptive licensing pilot and other ways regulators can support innovation
  • 10:30 Morning Coffee

    11:00 Empower: What led to the Early Access to Medicines Scheme?

    Professor Sir Peter Lachmann

    Professor Sir Peter Lachmann, Emeritus Professor of Immunology, University of Cambridge

  • Why the process of drug regulation is broken and how it can be mended.
  • The Empower campaign and the Halpin Protocol: how can we achieve earlier access to medicine for patients without encouraging snake oil salesmen?
  • Welcoming the Early Access scheme while encouraging further reform
  • 11:40 Pricing, Policy and Reimbursement of the Health Technology Assessment

    Josie Godfrey

    Josie Godfrey, Associate Director, Highly Specialised Technologies, NICE

    12:20 Networking Lunch

    13:20 Chairs Afternoon Opening Remarks

    Deborah O'Neil

    Deborah O'Neil, Chief Executive Officer, Novabiotics Ltd

    13:30 Orphan Drugs in Germany

    Bertram Häussler

    Bertram Häussler, Chairman of the Board of Management, IGES Institut.

    14:10 Repurposing of orphan drugs for other orphan indications

    Deborah O'Neil

    Deborah O'Neil, Chief Executive Officer, Novabiotics Ltd

  • Important not to overlook the potential of expanding the utility of orphan treatments by repurposing for other, often very different, rare disease indications; numerous orphan drugs will have this potential
  • An attractive route to new rare disease therapies that has distinct advantages over repurposing non-orphan molecules and also re-profiling orphan meds for non-orphan indications
  • NovaBiotics’ Lynovex is one example of a repurposed orphan-orphan therapeutic
  •  

    14:50 Afternoon Tea

    15:20 Aspects linked to the developments of gene and cell products for Rare Diseases

    Didier Caizergues

    Didier Caizergues, Director, Department of International Regulatory Affairs, GENETHON

  • An explanation of the factors linked to gene and cell therapy
  • Assessing the new technologies and how we move forward in the field of rare diseases
  • 16:00 Early Access to Orphan Drugs - the rationale, challenges and options available

  • Why consider Early Access?
  • What are the challenges for Early Access?
  • Introduction to the mechanisms, regulatory environment and options for Early Access.
  • Insight into the potential benefits and risks of Early Access
  • Mark Corbett

    Mark Corbett, Vice President, Clinigen Global Access Programs (GAP), Clinigen

    16:40 FIRST EVER - Market Access and Commercialization Break-Through

    CheckOrphan is launching the first Access Program database (also known as: early access programs, compassionate use programs, or managed access programs). Learn how your company or entity can enter its program(s) in a compliant manner and provide more transparency about your Access Program.

    ·    Access Program database for orphan products and rare diseases
    ·    Overview of the registrar’s compliancy
    ·    Open for all – companies, service providers, government and NGOs
    ·    Receive your private access to update your entries
    Robert Derham

    Robert Derham, Co-Founder, CheckOrphan

    Holly Lumgair

    Holly Lumgair, Strategic Services Consultant and Patient Advocacy Manager, IDIS Pharmaceuticals

    17:00 PANEL DEBATE: Funding Drug Development

  • Evaluating investment and innovation
  • What are investors looking for?
  • Forming cross-stakeholder partnerships and strategic partnerships
  • Tony Hall

    Tony Hall, Co-Founder, Findacure Foundation

    Christopher  Hart

    Christopher Hart, Information Practice leader, AstraZeneca

    Gunter  Harms

    Gunter Harms , Market Access & Public Affairs Director, Shire Pharmaceuticals

    17:30 Chairs Closing Remarks and Close of Day One

    Sylvain Forget

    Sylvain Forget, COO, GMP Orphan SAS

    8:30 Registration & Coffee

    9:00 Chairs Opening Remarks

    Dario DiSimone

    Dario DiSimone, Sr. Director, Head of Rare Disease Europe, Pfizer

    9:10 The forecast for 2015 and where will we be ten years from now?

    Tim  Miller

    Tim Miller, President & CEO, Abeona Therapeutics

  • Advances in Rare Disease treatments, what’s looking promising? 
  • Evaluating the benefits of partnerships and patient groups
  • Assessing clinical development and future hurdles to access Orphan Drugs
  • 9:50 Repositioning in the orphan arena, a real life approach

    Sylvain Forget

    Sylvain Forget, COO, GMP Orphan SAS

  • What about the patent?
  • What about the price?
  • What about innovation?
  • 10:30 Morning Coffee

    11:00 Talking Initiatives, Frameworks and Collaborations in Rare Disease Research

    Dario DiSimone

    Dario DiSimone, Sr. Director, Head of Rare Disease Europe, Pfizer

    11:40 Creating a Culture of Innovation in the field of Orphan Drugs and Rare Diseases

    Dominic Nutt

    Dominic Nutt, Director of Communications, M&C Saatchi

  • Introduction and Overview
  • Reviewing the Medical Innovation Bill going through Parliament to allow doctors to prescribe off-label medicines to patients with no alternative, without fear of prosecution if something goes wrong
  • Alleviating the legal responsibility off the Doctor’s shoulders when prescribing medicines
  • A quick insight into compassionate use programmes and facilitating its approval in the EU
  • 12:20 Networking Lunch

    13:20 Chairs Afternoon Opening Remarks

    Dominic Nutt

    Dominic Nutt, Director of Communications, M&C Saatchi

    13:30 Non industry led development for Rare Diseases

    Tony Hall

    Tony Hall, Co-Founder, Findacure Foundation

  • Empowering patient groups to lead the drug development process
  • Academia-led drug development
  • Open access drug development
  • 14:10 Early Access to Medicines Scheme - A Patient Perspective

    Emily  Crossley

    Emily Crossley , Founder and Director, Duchene Children's Trust

    14:50 Afternoon Tea

    15:20 Clinical trials in a world with social media

    Christopher  Hart

    Christopher Hart, Information Practice leader, AstraZeneca

  • Monitoring clinical trials and patient recruitment – the promises of social media
  • Listening to patients with social media
  • Overcoming the challenges of social media
  • 16:00 Challenges of the setup of large clinical trials for Orphan Drugs

    Camille Metais

    Camille Metais, Associate Director, Regulatory Affairs Manager, Alexion Pharmaceuticals Inc

  • Review of the current Clinical trial regulations worldwide
  • Specific challenges for Orphan drugs
  • Case study/examples
  • Is the new Clinical trial regulation expected to improve the current situation?
  • 16:40 Chairs Closing Remarks and Close of Day Two

    Dominic Nutt

    Dominic Nutt, Director of Communications, M&C Saatchi

    +

    FEATURED SPEAKERS

    Bertram Häussler

    Bertram Häussler

    Chairman of the Board of Management, IGES Institut.
    Camille Metais

    Camille Metais

    Associate Director, Regulatory Affairs Manager, Alexion Pharmaceuticals Inc
    Christopher  Hart

    Christopher Hart

    Information Practice leader, AstraZeneca
    Daniel  O'Connor

    Daniel O'Connor

    Medical Assessor, MHRA
    Dario DiSimone

    Dario DiSimone

    Sr. Director, Head of Rare Disease Europe, Pfizer
    Didier Caizergues

    Didier Caizergues

    Director, Department of International Regulatory Affairs, GENETHON
    Dominic Nutt

    Dominic Nutt

    Director of Communications, M&C Saatchi
    Emily  Crossley

    Emily Crossley

    Founder and Director, Duchene Children's Trust
    Gunter  Harms

    Gunter Harms

    Market Access & Public Affairs Director, Shire Pharmaceuticals
    Josie Godfrey

    Josie Godfrey

    Associate Director, Highly Specialised Technologies, NICE
    Professor Sir Peter Lachmann

    Professor Sir Peter Lachmann

    Emeritus Professor of Immunology, University of Cambridge
    Tim  Miller

    Tim Miller

    President & CEO, Abeona Therapeutics
    Tony Hall

    Tony Hall

    Co-Founder, Findacure Foundation

    Bertram Häussler

    Chairman of the Board of Management, IGES Institut.
    Bertram Häussler

    Camille Metais

    Associate Director, Regulatory Affairs Manager, Alexion Pharmaceuticals Inc
    Camille Metais

    Christopher Hart

    Information Practice leader, AstraZeneca
    Christopher  Hart

    Daniel O'Connor

    Medical Assessor, MHRA
    Daniel  O'Connor

    Dario DiSimone

    Sr. Director, Head of Rare Disease Europe, Pfizer
    Dario DiSimone

    Deborah O'Neil

    Chief Executive Officer, Novabiotics Ltd
    Deborah O'Neil

    Didier Caizergues

    Director, Department of International Regulatory Affairs, GENETHON
    Didier Caizergues

    Dominic Nutt

    Director of Communications, M&C Saatchi
    Dominic Nutt

    Emily Crossley

    Founder and Director, Duchene Children's Trust
    Emily  Crossley

    Gunter Harms

    Market Access & Public Affairs Director, Shire Pharmaceuticals
    Gunter  Harms

    Holly Lumgair

    Strategic Services Consultant and Patient Advocacy Manager, IDIS Pharmaceuticals
    Holly Lumgair

    Josie Godfrey

    Associate Director, Highly Specialised Technologies, NICE
    Josie Godfrey

    Mark Corbett

    Vice President, Clinigen Global Access Programs (GAP), Clinigen
    Mark Corbett

    Professor Sir Peter Lachmann

    Emeritus Professor of Immunology, University of Cambridge
    Professor Sir Peter Lachmann

    Robert Derham

    Co-Founder, CheckOrphan
    Robert Derham

    Samantha Parker

    VP RRD Foundation and Director of external affairs and rare disease partnerships, Orphan Europe (UK) Ltd
    Samantha Parker

    Sylvain Forget

    COO, GMP Orphan SAS
    Sylvain Forget

    Tim Miller

    President & CEO, Abeona Therapeutics
    Tim  Miller

    Tony Hall

    Co-Founder, Findacure Foundation
    Tony Hall

    Sponsors and Exhibitors

    Supporters

    Workshops

    Assessing regulatory Requirements for Orphan Drugs
    Workshop

    Assessing regulatory Requirements for Orphan Drugs

    Holiday Inn Regents Park
    22nd October 2014
    London, United Kingdom

    Developing novel biologic therapies for rare and orphan diseases
    Workshop

    Developing novel biologic therapies for rare and orphan diseases

    Holiday Inn Regents Park
    22nd October 2014
    London, United Kingdom

    Gunter Harms Interview

    Download

    Sponsors and Exhibitors


    Clinigen Group Plc

    Sponsors and Exhibitors
    http://www.clinigengroup.com

    Clinigen Group plc is a fast-growing specialty global pharmaceuticals and services business, dedicated to serving patients, the medical community and the healthcare industry to supply critical life-saving treatment. With offices in the UK, US and Japan, Clinigen is focused on delivering the right drug, to the right patient, at the right time, whether it’s for clinical trial, individual patient need, or as a fully licensed treatment to fulfil a need in niche global markets.

    Clinigen GAP (Global Access Programs) is the division that specializes in the consultancy, development, management and implementation of access programs for pharmaceutical and biotechnology companies. It is able to provide clients with a fully outsourced solution for managing access to medicines which are unlicensed in one or multiple markets. Clinigen’s dedicated and highly experienced team combines pharmaceutical and service expertise, executing innovative programs that effectively manage the needs of all stakeholders.


    Novabiotics Ltd

    Sponsors and Exhibitors
    http://www.novabiotics.co.uk

    NovaBiotics is a leading clinical-stage speciality biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (NM001; Lynovex®). NovaBiotics first-in-class therapeutics offer a potential solution to a looming global anti-infectives crisis; one driven by antibiotic and antifungal drug resistance and the rise of emerging pathogens in a number of infectious conditions including the orphan condition cystic fibrosis.

    Media Partners


    Thomson Reuters

    Supporters
    http://thomsonreuters.com/products_services/science/

    Thomson Reuters is the leading source of intelligent information for professionals around the world. We provide essential information to keep you in touch with the rapidly-changing pharmaceutical and chemical markets, expert services to help you make informed, early decisions, and intuitive technology to manage and support your discovery and development activities. Our products give you the intelligence, tools and expertise to help you optimize your IP portfolio, monitor industry developments, identify licensing and partnering opportunities, deliver successful regulatory submissions, and support your scientific messaging, marketing, product positioning, and awareness campaigns.


    KONGPOSH Publications

    Supporters
    http://www.kppub.com

    KONGPOSH Publications is one of India’s leading Pharma Publishers. The Pharma Review® is a bi-monthly article based journal covering various fields of pharmacy. Participation and distribution in over 30 Expos & Conferences worldwide each year. It is widely read by decision makers, middle management and the academia. Also available in E-book format. Other publications : Indian Pharma Reference Guide (Annual) – Names and address of Pharmaceuticals, Bulk Drugs, Machinery’s & Instrumentation, AYUSH Manufacturers; and much more; High Performance Thin Layer Chromatography; Elements of Pharmacovigilance; Regulation of Clinical Trials; AYUSH (CD); NDDS/AMD (CD)


    Bioportfolio Limited

    Supporters
    http://www.bioportfolio.com

    BioPortfolio.com is a leading news, information and knowledge resource covering the global life science industries impacted by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to source core information on specific bio-related topics, to collate relevant data associated with each topic and to point the user to relevant knowledge resources


    Inpharm

    Supporters
    http://www.inpharm.com

    Pharmafocus' exclusive editorial looks at the impact of developments within the pharmaceutical industry, combining headline news with in-depth features and analysis. Sign up for weekly email newsletters! Pharmafile is the key resource for people who need to source specialist suppliers of goods and services within the pharmaceutical and related industries. Pharmafile contains details of thousands of pharmaceutical, biotech, diagnostic, medical devices and animal healthcare sites. InPharmjobs.com provides a comprehensive specialist online recruitment service for the pharmaceutical industry, it lists thousands of vacancies. Sign up today for unique job alerts direct to your email.


    Drug Discovery World

    Supporters
    http://www.ddw-online.com

    For over a decade DDW has continued to be the ‘must read’ journal within the DD&D Arena. DDW is recognised for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised platform for Industry Gurus to debate some of the more challenging technological and business issues facing the the life science industry. DDW adheres to the maxim..... ‘Turning Science into Business’ DDW examines the advances in new technologies and the associated implications within the context of developing new and efficacious therapeutics. DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level, allowing both camps to profit from the uncomplicated style of editorial but at the same time challenges our readers to look at new ways to overcome discovery bottlenecks, embrace nascent technologies and build next generation technology platforms.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    Orphan Druganaut

    Supporters
    http://www.OrphanDruganaut.wordpress.com

    Provides competitive intelligence, news, Internet Buzz on global orphan drug developments and rare diseases.


    Pharma Marketing News

    Supporters
    http://www.news.pharma-mkting.com/

    Pharma Marketing News is an independent monthly electronic newsletter focused on issues of importance to pharmaceutical marketing executives. It is a service of the Pharma Marketing Network -- The First Forum for Pharmaceutical Marketing Experts -- which brings together pharmaceutical marketing professionals from manufacturers, communications companies, and marketing service providers for wide ranging discussions and education on a multitude of current topics. Pharma Marketing Network & Pharma Marketing News provide executive-level content coupled with permission-based e-marketing opportunities.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Antibodies Online

    Supporters
    http://www.antibodies-online.com

    antibodies-online.com facilitates researchers to find the appropriate antibodies for their respective research project. As an independent and multi-vendor marketplace for research antibodies and thanks to the cooperation with more than 130 different manufacturers, a large selection of Antibodies (over 700,000), ELISA Kits (over 130,000), Secondary Antibodies (17,000), Proteins (130,000), Peptides and Isotype Controls is available. By supporting the Independent Validation Initiative and the Resource Identification Initiative, antibodies-online.com also addresses the important topics of transparent product quality and scientific reproducibility. In addition scientists receive news and detailed information about the individual antibodies from databases such as the PubMed and others.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


    Life Science Global

    Supporters
    http://www.lifescienceglobal.com/

    Lifescience Global aims to publish peer-reviewed research journals covering wide range of academic disciplines. Our aim is to maintain the highest standards of review through internationally-recognized editorial teams. In addition, we also provide publishing and e-marketing services to Universities, Conferences and Research Institutions for their niche scholarly market requirements.


    GenomeWeb

    Supporters
    http://www.genomeweb.com

    GenomeWeb LLC is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.

    GenomeWeb’s editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics.

    GenomeWeb readers can be found in major biopharmaceutical companies, top research universities, biomedical institutes, and government laboratories.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Cutting Edge

    Supporters
    http://www.cuttingedgeinfo.com

    Cutting Edge Information provides customized research and benchmarking reports to pharmaceutical, biotechnology and other life science companies. We provide off-the-shelf and customized research for key areas including medical affairs, clinical development, market access, regulatory affairs, marketing management, sales and HCP fair market value.


    Global Data

    Supporters
    http://store.globaldata.com

    GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    Labhoo Limited

    Supporters
    http://www.labhoo.com



    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


    Innovations in Pharmaceutical Technology (IPT)

    Supporters
    http://www.iptonline.com/

    Innovations in Pharmaceutical Technology (IPT) magazine offers in-depth comment and analysis written by experts from within the field. IPT covers the latest developments in drug discovery, laboratory technology, formulation, delivery systems, and other insights and innovations in the field. The magazine also presents sector-specific events, company and individual profiles, and reviews. IPT is a platform for those involved in pharmaceuticals and biotechnology to share their ideas with other key industry figures.

    Now you can also read IPT on the go with the new Samedan app. Click here to download the app for your iPhone or iPad: http://bit.ly/IJECug


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Global Biodefense

    Supporters
    http://www.globalbiodefense.com/

    Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.


    Journal of Rare Disorders

    Supporters
    http://www.journalofraredisorders.com

    The Journal of Rare Disorders (JORD) is a new peer-reviewed, open access publication. The Journal focuses on all aspects of rare diseases, the science, progress on new therapies, new drugs, and issues of drug regulation and cost. There are no fees to publish and we offer viewers barrier free full text articles for download.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.